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Background: CTL escape mutations have been described during acute hepatitis C in patients who developed
chronic disease later on. Our aim was to investigate the mutual relationship between HCV specific CD8+ T cells
and evolution of the viral sequence during early acute HCV infection.
Results: We sequenced multiple clones of NS3 1406 epitope in 4 HLA-A*02 patients with acute hepatitis C
genotype 1b infection. Pentamers specific for the variants were used to monitor the corresponding CD8+ T cell
response. We observed outgrowth of mutations, which induced only a weak and thus potentially insufficient CD8+
T cell response. In one patient we observed outgrowth of variant epitopes with similarities to a different genotype
rather than de novo mutations most probably due to a lack of responsiveness to these likely pre-existing variants.
We could show that in acute hepatitis C CTL escape mutations occur much earlier than demonstrated in previous
studies.
Conclusions: The adaption of the virus to a new host is characterized by a high and rapid variability in epitopes
under CD8+ T cell immune pressure. This adaption takes place during the very early phase of acute infection and
strikingly some sequences were reduced below the limit of detection at some time points but were detected at
high frequency again at later time points. Independent of the observed variability, HCV-specific CD8+ T cell
responses decline and no adaption to different or new antigens during the course of infection could be detected.
Keywords: Acute hepatitis C, Quasispecies, T cell, Escape mutation, EpitopeBackground
Hepatitis C virus (HCV) causes acute and chronic hepa-
titis. The mechanisms that determine progression to
chronic infection and outcome of HCV infection are not
well understood. It is generally assumed that strong
cellular immune responses are associated with viral
clearance in acute hepatitis C infection [1-3]. Outcome
of HCV infection is usually determined during the first
weeks of acute infection. Recent data evidence selective
pressure on HCV mediated through the HLA class I* Correspondence: Norbert.Gruener@med.uni-muenchen.de
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distribution, and reproduction in any mediummolecules and indicate that CD8+ T cell selection pres-
sure influences viral evolution. However, there have been
no studies in humans examining sequence evolution and
contribution of CD8+ T cells during the early phase.
The study by Tester et al. [4] followed two individuals
acutely infected from a single source. An escape muta-
tion was observed in the recipient who did not sponta-
neously resolve infection. Cox et al. [5] defined escape
mutations in multiple CTL epitopes in eight acutely
infected individuals. In a third study by Urbani et al. [6],
escape mutations were found 1 and 3 months after onset
of acute disease. Timm et al. [7,8] described escape mu-
tations within epitope HLA B8 1395. The sequence in
these studies usually was determined several monthsntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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model were able to analyze very early viral evolution in
acute HCV infection and found a correlation between
outgrowth of escape mutations and the clinical outcome
[9,10]. Although these studies constitute a critical mass
of evidence for CTL escape mutations in HCV infection
many questions, including timing, variability and whether
these sequence changes represent outgrowth of particular
clones of pre-existing quasi species or de novo mutations,
remain to be answered.
In CTL epitope regions, especially of genotype 1b,
gene diversity is significantly higher in NS3 than in other
proteins [8,11]. We therefore investigated 4 patients du-
ring acute infection with genotype 1b and followed their
response and evolution of variants within NS3 1406
epitope very early after onset of symptoms. Our results
demonstrate that NS3 1406-specific, IFN-γ-secreting T
cells can exert immune pressure resulting in extinction
of certain strains. We observed outgrowth of mutations,
which induced only a weak and thus potentially insuffi-
cient CD8+ response. In one patient we observed out-
growth of variant strains, which were more similar to
sequences from a different genotype rather than random
de novo mutations most likely due to a lack of responsive-
ness to these pre-existing strains. HCV-specific CD8+
T cell responses induced very early during infection
seem to be unable to adapt to different or new anti-
gens during the course of infection.
Results
Viral evolution within NS3 1406 epitope and
corresponding T cell response in patients with acute
hepatitis C
The NS3 region of the HCV genome including the NS3
1406 epitope was amplified by PCR and multiple clones
were sequenced. We focused on the well-characterized
CD8 T-cell epitope NS3 1406–15 with HLA-A0201* re-
striction, which has already been described in the context
of escape mutations [4,11]. In patient 1, the sequence was
KLSGLGINAV in 12 of 12 clones at the beginning of acute
disease (week 1). At that time 4.32% of CD8+ T cells were
specific for KLSGLGINAV. At the same time, 3,43% CD8+
T cells could be stained with pentamer KLSGLGINAI,
3.45% with pentamer KLSGLGLNAV and 0.47% with
pentamer KLLGLGINAV. However, these sequences were
not detected before week 2 (KLSGLGINAI), week 4
(KLSGLGLNAV) and week 7 (KLLGLGINAV) (Additional
file 1: Table S1). At week 2, mutations developed at po-
sition 1415 in 16 of 16 clones (KLSGLGINAI). At week 3,
the original sequence KLSGLGINAV again occurred in all
13 clones, at this time with a mutation in the flanking re-
gion. One week later, the sequence of week 2 was detected
again in 7 of 11 clones, while in 4 of 11 clones a novel se-
quence (KLSGLGLNAV) was found. Pentamer staining atweek 4 revealed the highest percentage of NS3 1406-
specific CD8+ T cells in comparison to all other time
points. Over time, staining at the different time points
revealed the highest direct ex vivo frequencies for
KLSGLGINAV followed by KLSGLGINAI, KLSGLGLNAV
and KLLGLGINAV. This relative proportion of these
variant-specific CD8+ T cells remained unchanged during
the course of disease despite a high fluctuation of se-
quences and viral load found at the different time points
(Figure 1). The specific cells were also stained with anti-
CD38. Expression of CD38 dropped in all variants over
time until week 251. In week 5, the sequence of week 2
KLSGLGINAI was again the dominant sequence in all 14
clones tested. At week 7, a previously undetected sequence
(KLLGLGINAV) was found in 10 of 12 clones. At week 34,
KLSGLGLNAV was the only sequence found in 12 of 12
clones. Between week 6 and week 34, no amplification was
possible due to a low viral load. Given the high variability
within the NS3 1406 epitope, there were fluctuating
HCV RNA levels during acute infection. At week 1, a
high viral load was found, rapidly dropping within 7 days
and again increasing ten-fold during another 7 days
(Additional file 1: Table S1). Another 3 weeks later, the
viral load again dropped 100-fold. Within the following
week, a new 100-fold increase was observed. Then a 1000-
fold decrease occurred in the next 2 weeks and viral load
remained low for several months. By week 37, another
increase of the viral load to 4046157 cp/ml was observed.
At that time, therapy with pegylated interferon and ribavi-
rin for 48 weeks was started; due to a sustained virological
response no virus was detectable in the follow-up period.
However, 164 and 251 weeks after acute disease, still
significant numbers of NS 3 1406-specific CD8+ T cells
were detectable, again with the same relative proportion.
In patient 2, HCV RNA was positive at three time
points. At week 2, KLSGLGINAI was dominant in 13 of
13 clones. One week later, KLVALGINAV was the main
sequence in 22 of 26 clones. This sequence resembles
the genotype 1a sequence. After this, no virus was de-
tectable until week 13. At that time, the initial sequence
of week 1 was again the dominant sequence in 17 of 17
clones (Additional file 2: Table S2a).
In patient 2, the viral load in week 2 was 233477 cp/ml,
remaining identical in week 3. In week 4, no virus was
found. In week 13, again 71047 cp/ml were detectable.
At week 3, in patient 2, 1% of the CD8+ T cells specific
for NS3 1406 KLVALGINAV and low frequency of
KLSGLGINAV and KLSGLGLNAV could be stained. Du-
ring further follow-up, frequencies dropped to 0.1% for
NS3 1406 KLVALGINAV and below detection limit for
KLSGLGINAV and KLSGLGLNAV (Figure 2). Patient did
not receive treatment and was lost to follow-up.
In patient 3, a mixed population was found with
KLSGLGLNAV in 21/26 clones and KLSGLGINAI in 4/26
Figure 1 Direct ex vivo peripheral blood frequency of HCV specific CD8+ T cells by ex vivo pentamer staining in patient 1. Four
different time points at week 2, 4, 164 and 251 after onset of acute disease are given. Pentamers with specifity for KLSGLGINAV, KLSGLGINAI,
KLSGLGLNAV and KLLGLGINAV were used. The percentages of NS3 1406 specific CD8+ T cells/CD8+ T cell total are given. The percentages of
CD38+ specific CD8+ T cells/NS3 1406 specific CD8+ T cells are given in brackets.
Figure 2 Peripheral blood frequency of HCV specific CD8+ T cells by ex vivo pentamer staining. Frequencies in patient 2. Frequencies in
patient 3. Different time points after onset of acute disease are given. Pentamers with specifity for KLSGLGINAV, KLSGLGLNAV, KLVALGINAV
were used.
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found in 12/23 clones and KLSGLGINAI in 11/23 clones.
At that time, therapy was started and no virus was detec-
table during follow-up (Additional file 2: Table S2b).
In patient 3, 833400 cp/ml were found in week 2. The
viral load dropped to 17335 cp/ml in week 3. At that
time, therapy was started and no virus was detectable in
the follow-up period.
In patient 3, only low frequencies of KLSGLGINAV
and KLSGLGLNAV specific CD8+ T cells were detec-
table at week 3. No NS 3 1406-specific CD8+ T cells
were detectable thereafter (Figure 2).
In patient 4, sequencing of NS3 1406 was done at
week 2, week 15 and week 22. No mutations were
observed during this period. At all 3 time points,
KLSGLGINAI was found as main sequence. At the other
time points, no virus was detectable. HCV RNA was de-
tectable in week 4 but no amplification of the epitope
was possible at that time (data not shown).
In patient 4, the viral load was low in week 1. No virus
was detectable in week 9. In week 2, 15 and 22, a low viral
load was detectable. After week 22, no virus was found.
In patient 4, no NS 3 1406-specific CD8+ T cells were
detectable at any time. An immediate therapy with
pegylated interferon was started in week 2 and a sustained
virological response was achieved in this patient.
Viral evolution within NS3 1317–1423 outside NS3 1406
Since variability of epitopes can be influenced by their
flanking regions, we also analyzed the variability of the se-
quences outside NS3 1406. Sequence data of NS3 1317–
1423 revealed that the high variability detected within the
epitope 1406 in patient 1 could not be detected within
NS3 1317–1423. In contrast the sequence was very stable
over time (Additional file 2: Table S2c). Only at the time
when the viral load came up again (week 37) a mutation
within patient’s HLA-A02* restricted NS3 1321–35 epi-
tope (TDSTSILGIGTVLDQ) to NS3 1321–35 epitope
(IDSTSILGIGTVLDQ) was observed. Another mutation
was found at position 1282 V to I, which represents the
flanking region of patient’s HLA-A02* restricted NS3
1284–1296 epitope [12].
Also in patient 2 and 3 sequence variations were found
within known CTL epitopes, NS3 HLA-A02* 1321–35
[13], HLA-B35* NS 3 1359–67 [14], NS3 1382-1397 [5],
HLA-B08* NS3 1395–1403 [15] or the direct flanking
region of known CTL epitope HLA-C14*1371-80 [5]). In
patient 2 at week 2 patient’s HLA-A02* restricted NS3
1321–35 TDSTSILGIGTVLDQ was found, at week 3 a
sequence variation at position 1323 was detected, NS3
1321–35 TDATSILGIGTVLDQ. 6 weeks later again the
initial sequence came up. Mutations were also found in
epitopes which did not match with patient’s HLA. NS 3
1359–67 epitope HSNIEEVAL was sequenced at week 2.Amino acid exchange at position 1360 could be detected
at week 3 HPNIEEVAL. Again at week 9 the initial se-
quence was found. The same phenomenon was observed
within NS3 1382–97. IETIKGGRHLIFCH (week 2) to
LEVIKGGRHLIFCH (week 3) and back to IETIKGG
RHLIFCH (week 9). At position 1369, the flanking re-
gion of NS3 1371–80, amino acid exchange N (week 2)
to T (week 3) to N (week 9) was found. In patient 3
matching HLA-A02* restricted NS3 1321–35 TDSTTIL
GIGTVLDQ and NS3 1321–35 TDSTSILGIGTVLDQ
were found at week 3 and 4. Another sequence variation
was observed within patient’s HLA-B08* restricted NS3
1395–1403 epitope. HSKRKCDEL and HSRKKCDEL
were present at week 3 and 4. This mutation has been
described frequently in the presence of HLA B*08 allele
[7,16]. At position 1370, the flanking region of NS3
1371–80, amino acid exchange I (week 3) to T (week 4)
was found.
Thus all sequence variations in NS3 were observed
within known CTL epitopes or in their flanking regions.
The ongoing variation was seen mainly in patient’s HLA
restricted epitopes. Only in patient 2 variations were
found in patient’s HLA non-restricted epitopes (NS3
1359–67, NS3 1382–97). For the HLA-C14 restricted
NS3 1371–80 epitope the patient’s corresponding HLA
was unknown. At least in patient 2 the sequence vari-
ation found might reflect different pre-existing strains
since the main sequence at week 2 and 9 were identical.
In addition the main sequence found in week 3 differed
at 8 positions from the main sequence at week 2/9. Fur-
thermore the main sequence with the KLVALGINAV
epitope is usually found in genotype 1a infected patients
in contrast to the KLSGLGINAI sequence usually found
in genotype 1b infected patients [17]. In addition varia-
tions were found in patient’s HLA non-restricted epi-
topes indicating different strains rather than ongoing
selection pressure. As another variation KLSGLGLNAV
occurred in 4/22 clones either as a consequence of
mutations from week 2 sequences or also as already pre-
existing so far undetected variation. The complete re-
duction of the main sequence below the detection
threshold within a few days and reappearance at a later
time point might be caused by the ongoing selection
process in acute infection and the fluctuations in viral
load, which could drop below the detection limit of our
methods. This was observed in patient 1 as well as in
patient 2.
Induction of γ-interferon production of PBMC after
stimulation with different NS3 1406 epitopes
To further address the question whether the mutations
seen in acute hepatitis C infection resemble escape mu-
tations we investigated the ability to induce production
of γ-IFN of PBMC early (week 4) and late (week 251)
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other time points due to lack of patient material. The pro-
duction of γ-IFN of PBMC after stimulation with wild
type or mutant peptides was tested with ELISpot assay as
described in material and methods. After stimulation we
found that the initial sequence KLSGLGINAV was able to
induce high amounts of γ-IFN (> 200 specific spots/2 ×
105 PBMC). KLSGLGLNAV, which was found at week 37
in all clones induced significantly less γ-IFN (Figure 3).
T cell clones and cross reactivity
CD8+ T cell clones specific for KLSGLGINAV and
KLSGLGLNAV were generated. Staining of these T cell
clones revealed cross reactivity of pentamer KLSGL
GINAV and KLSGLGLNAV. Staining of the clone
KLSGLGINAV with pentamer KLSGLGLNAV and vice
versa was possible (Figure 4).
Discussion
In our study of sequence variations within NS3 1406
epitope during early acute HCV, we observed several
features, which potentially contribute to the develop-
ment of chronic infection. We demonstrated an ex-
tremely high variability within this epitope during the
first weeks. A particular characteristic were significant
changes in the frequency of different variants with some
being reduced below the limit of detection at some time
point but being detected at high frequency again a few
days later on. No new T cell responses were detected in
response to mutant peptides. The mutated variants
found were characterized by a reduced capacity to in-
duce IFN-γ. The rapid and high mutation rate was ob-
served mainly within epitope NS3 1406. In contrast,
NS3 1317–1423 was characterized by rare mutations,Figure 3 Enzyme-linked immunospot (ELISPOT) results for patient 1.
stimulated with 20 μg/ml of NS3 1406 peptides as indicated for 48 h, and
as described in material and methods. Each bar represents the specific spo
acute infection) are shown. The error bars represent the standard error of tmost of them detectable within patient’s HLA restricted
known epitopes. Not only the original sequence but also
variant sequences found during early infection dropped
below the limit of detection transiently and reappeared
during further follow-up. This alternation of sequences
was observed over several weeks in patient 1. In patient
1, at week 3 the sequence KLSGLGINAV, which has
been detected at week 1 as main sequence in 12/12
clones, occurred again in 13/13 clones; however, this
time with a mutation in the flanking region. Interes-
tingly, at week 2, this sequence could not be detected in
16 clones analyzed. Therefore, this mutation in the
flanking region of the epitope may favor the transient re-
occurrence of the original sequence i.e. by changing the
pattern of proteasome digestion. This mechanism has
recently been described by Kimura et al. in chimpanzees
[18]. A similar phenomenon of vanishing and reoccur-
rence of sequences was seen in patient 2. However, the
sequences found at different time points resembled
index sequences of different genotypes and might reflect
rather pre-existing variations than random de-novo mu-
tations. In contrast to patient 1, the sequence that re-
occurred in patient 2 was not recognized by specific
CD8+ T cells at all. NS3 1406-specific CD8+ T cells were
found against the presumably genotype 1a sequence but
not against the putative genotype 1b sequence. This is
remarkable since this suggests that CTL escape is not
the only selection criteria. Despite mutations or pre-
existing variants that result in the production of new or
different potential antigens, our data give evidence that
no new CD8+ T cell responses were generated against
the new variants that were found during infection. This
interpretation is supported by different observations.
Pentamer staining was positive for all variants in patientPeripheral blood mononuclear cells (PBMC) from patient 1 were
the interferon-gamma production was measured in the ELISPOT assay
ts/2 × 105 PBMC. Two different time points (4 and 251 weeks after
he mean.
Figure 4 64 weeks after disease onset of patient 1 and after successful interferon therapy clones were generated with specificity for
KLSGLGLNAV and KLSGLGINAV as it is indicated on the y-axis. The different clones were tested with pentamers as indicated on the x-axis.
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mains unclear if these different specific CD8+ T cells
have been induced very early or if this reflects cross re-
activity between the variants. The proportion of these
variant-specific CD8+ T cells remained stable over a long
period of time, which rather indicates cross reactivity
and a lack of new variant-specific CD8+ T cells over
time. In addition, the activation marker CD38 dropped
during the course of infection in all pentamer-positive
CD8+ T cells in patient 1 despite a high variability in se-
quence and viral load during this phase. It has been
reported earlier by us that HCV-specific CD8+ T cells
are induced but not sustained [19]. In extension to our
former observation, this holds true despite the proven
high variability of sequence and viral load. Furthermore,
using specific CD8+ T cell clones from patient 1, we
demonstrated cross reactivity of the pentamer staining
for variant epitopes. In patient 2, we found two different
strains during the course of acute disease. These se-
quences are usually found in different genotypes (1a and
1b). One possible explanation is that these variants cor-
respond to pre-existing variants rather than random de-
novo mutations. However, specific CD8+ T cells were
only observed against the genotype 1a epitope but not
the genotype 1b epitope. All these findings support a
lack of generation of new variant-specific CD8+ T cells
against mutant or pre-existing variants during acute
HCV infection despite a high variability in sequence and
viral load. This phenomenon has been observed by
others as well [5,6]. Explanation for this observation hadbeen that original antigenic sin [20] may be responsible
for the lack of response to mutant sequences or that the
mutant sequences cannot be processed effectively for
presentation. Differences were observed in terms of the
functional capacity of the different sequences. The initial
sequence in patient 1 was capable of inducing the highest
amounts of IFN-γ. Functionality with regard to IFN-γ pro-
duction remained high over time as we observed similar
IFN-γ levels after 251 weeks in patient 1. The mutated
variants were less potent or did not induce IFN- γ- pro-
duction at all. The variants that remained and were se-
lected by the virus were either less efficient in inducing
IFN-γ production (patient 1) or were not recognized by
CD8+ T cells due to a lack of priming of a response
specific for the corresponding variant (patient 2).
Several limitations need to be considered in this study.
The methods used might not be sensitive enough to de-
tect certain minor variants of the quasispecies. Thus, it
is difficult to distinguish between levels below the detec-
tion limit or complete disappearance of a variant. Add-
itionally, the sequence of the inoculum was unknown
but could have provided valuable information on the
pre-existing variants. Moreover our study mainly fo-
cused on a single epitope and its surrounding sequences.
Therefore it remains to be determined if mutations and
escape occurs as quickly at other CD8+ T cell epitopes.
Despite these limitations we had the opportunity, in
contrast to former studies, to gain our data very early
after acute disease and were thus able to find a high vari-
ability within a known CD8+ T cell epitope. This could
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our results and former studies. Kuntzen et al. [14] de-
scribed two patients who progressed to chronicity with-
out substantial escape in targeted epitopes. However, the
earliest sequence analysis was done 2 and 2.5 months
after acute infection. Thus, transient mutations with re-
appearance of former sequences could have been missed
in this study. In addition, this study found that muta-
tions outside envelope overall declined over the course
of infection. Taking this observation and our data to-
gether, sequence analysis within the first weeks or even
days after infection or acute disease may additionally
help to elucidate the role of CD8+ T cell escape muta-
tions in driving the evolution of HCV.
Outside the NS3 1406 epitope within NS3 1318–1423,
which was the region sequenced in our study, a low vari-
ability was found. Mutations almost exclusively affected
formerly described CTL epitopes or their flanking re-
gions. The ongoing selection was observed in patient’s
HLA restricted epitopes but not in patient’s HLA non-
restricted epitopes. The only exception found of a vari-
ation in HLA non-restricted epitopes (NS3 1359–67,
NS3 1382–97) in patient 2 can be either explained by
pre-existing different strains or, in the absence of on-
going selecting immune pressure, reversion of a muta-
tion to a more favourable sequence for the virus with
respect to viral replication. Our findings indicate that
the virus is very stable without immune pressure. Future
longitudinal analysis of the whole genome during the
early phase of acute infection should elucidate the hot
spots like NS3 1406 epitope. A better understanding of
these hot spots could be of outstanding importance for a
vaccine development.
Conclusions
In summary, we demonstrated that CTL escape muta-
tions occur much earlier than previously demonstrated
in acute HCV infection. The adaption of the virus to a
new host is characterized by a high and rapid variability
in epitopes under CD8+ T cell immune pressure. This
adaption takes place during the very early phase of acute
infection. Variants can drop below the limit of detection
during the course of infection and reappear at later time
points. Most strikingly, HCV-specific CD8+ T cell re-
sponses induced very early during infection seem to be
unable to adapt to different or new antigens during the
course of infection. Independent of the variability, the
CD8+ T cell response is not sustained sufficiently. This
phenomenon indicates that different complementary
mechanisms are active in acute hepatitis C. Epitopes
under immune pressure evade by mutations but can re-
occur while the CD8+ response is already vanishing. A
better understanding of this peculiar silencing of the
CD8+ T cell response, which seems to be one of thehallmarks of acute hepatitis C, could be critical in fur-




In this study the following patients were included: 4 pa-
tients with acute hepatitis C infection. Time point zero
was defined as onset of symptoms and diagnosis of acute
HCV infection. Acute hepatitis C was diagnosed by do-
cumented seroconversion to anti-HCV antibodies or all
of the following: acute onset of hepatitis in previously
healthy individual, aminotransferases at least 10× the
upper limit of normal, exclusion of other infectious,
metabolic, or toxic causes of hepatitis, recent exposure
or source of infection identified. At different time points
during the course of disease patient 1, 3 and 4 received
antiviral treatment with subsequent viral elimination. Pa-
tient 2 did not receive antiviral treatment. For further
clinical characteristics of the patients see Table 1. Fur-
ther inclusion criteria were HLA-A0201 genotype and
positive tetramer staining with the NS3 1406–1415
index pentamer. All patients gave informed consent to
participate in the study and the protocol and the pro-
cedures of the study were conducted in conformity
with the ethical guidelines of the Declaration of
Helsinki. The study was approved by local ethical
committee, University of Munich. None of the patients
were enrolled in any previous studies.
Preparation of peripheral blood mononuclear cells
Peripheral blood mononuclear cells (PBMC) were isolated
by Ficoll-Hypaque density centrifugation (Biochrom,
Berlin, Germany) of fresh heparinized peripheral blood.
Briefly, PBMC were washed four times in phosphate buff-
ered saline (PBS), counted and resuspended in 1,5 ml FCS
supplemented with 10% DMSO. The maximum cell num-
ber per vial was 25 × 106. Cells were kept at −80°C for
24 hours before being transferred to −196°C. Thawing was
performed by inserting frozen probes in a prewarmed
water bath at 37°C. After thawing cells were immediately
washed in cell culture medium to remove residual DMSO
and resuspended in tissue cultured medium (RPMI
1640 medium; Gibco, Grand Island, N.Y.) containing
2 mM L-glutamine, 1 mM sodium pyruvate, 100 U of
penicillin per ml, 100 μg of streptomycin per ml and 5%
human AB serum.
HCV peptides and MHC class I pentamer staining on
PBMC
Peptides (10mers) were synthesized by Proimmune
(Oxford, UK) or EMC (Microcollections, Tübingen,
Germany). Lyophilized peptides were reconstituted at
20 mg/mL in dimethyl sulfoxide (Roth, Karlsruhe,
Table 1 Patients characteristics
ID Age Gender Treatment duration Antiviral treatment Possible transmission GPT IU/ml Genotype HLA A,B
1 57 m Week 38-93 Peg-interferon/ribavirin Unknown 1181 1b A2,A3,B7,Bw6
2 38 m None None Sexual 1996 1b A2,A26,B15,B51
3 63 m Week5-31 Peg-interferon Unknown 616 1b A1,A2,B7,B8
4 46 f Week2-28 peg-interferon Medical 647 1b A1,A2,B4,B51
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medium (Biochrom, Berlin, Germany).
Class I pentamers specific for different variants of HLA-
A02* restricted NS-3 1406 epitopes, which were detected
in our patients during acute HCV (KLSGLGLNAV,
KLLGLGINAV, KLSGLGINAI, KLSGLGINAV, KLVALG
INAV) were synthesized by Proimmune (Oxford, UK).
PBMC were stained in 100 μl medium (RPMI, 5% AB
serum, 2 mM glutamine, 50 U/ml Penicillin-Streptomycin)
with 10 μl of PE- or APC conjugated MHC class I penta-
mer for 30 minutes at room temperature according to the
manufacturer’s instructions. APC-conjugated anti-CD8,
PerCP-conjugated anti-CD14, PerCP-conjugated anti-
CD19, Viaprobe (Becton Dickinson), and FITC-conjugated
anti-CD38 monoclonal antibodies (Becton Dickinson)
were added for the last 20 minutes of incubation.Elispot assay
PBMC (2*105/well) from patients were tested with respect
to their interferon gamma production by a commercial
Elispot Kit system (ELISpotPRO for human interferon-γ,
MABTECH AB Büro Deutschland, Hamburg, Germany).
The assay was performed on bulk PBMC according to the
manufacturer’s instructions as previously described [3].
The spots were counted by an automated Elispot reader
(EliSpot Reader System, Autoimmun Diagnostika GmbH,
Straßberg, Germany). The following peptides were used
for stimulation: 1. KLSGLGINAV, 2. KLSGLGINAI, 3.
KLSGLGLNAV and 4. KLLGLGINAV.Generation of T-cell clone and specificity testing
PBMCs (5*104/well) of patient 1 were incubated in 96-
well U-bottom plates (TPP, Trasadingen, Switzerland) in
the presence of HCV peptides (10 μg/ml) in 150 μl of
tissue culture medium. On day six, recombinant inter-
leukin 2 (IL-2) was added to a final concentration of
200 U/ml (IL-2 was a gift of Basel Institute for Immun-
ology). On day 10 cells were cloned at 0,5 cells/well in
the presence of 3*104 irradiated PBMC per well, 200 U
of IL-2 per ml, and 2 μg per ml of phytohemagglutinin
(Murex Biotech Ltd., Kent, UK)). After 3 to 5 weeks
clones were tested for specificity by pentamer staining as
described above with minor modifications.
For expansion, T-cell clones were stimulated every 2
to 5 weeks with irradiated allogeneic PBMC in culturemedium with 200 U/ml IL-2 and 2 μg/ml PHA. Culture
medium was changed every 2–5 days.
HLA typing
DNA was obtained from whole blood using the QIAamp
DNA Blood Mini Kit following the manufacturer’s guide-
lines. HLA Class I typing was performed by PCR and/or
direct DNA sequencing by the Laboratory of Immunoge-
netics and Molecular Diagnostics, University of Munich.
HCV-RNA quantitation and genotyping
Sera were tested for HCV-RNA content and genotype by
real-time polymerase chain reaction (PCR) of the 5′ HCV
non-coding region as previously described [21,22]. Briefly,
RNA (4 ml) extracted from 50 μl of serum by the QIAamp
viral RNA kit (Qiagen S.A, Courtaboeuf, France) was
reverse-transcribed with the ThermoScript™ Reverse Tran-
scriptase kit (Gibco/BR, Cergy Pontoise, France) using
RC21 primer. Real-time PCR were carried out with 2 ml of
cDNA and RC1 and RC21 primers using the LC FastStart
DNA Master SYBER Green I kit and the LightCycler™
apparatus (Roche Diagnostics, Meylan, France).
Sequencing of autologous virus
Viral RNA was extracted from plasma samples using
Qiagen (Hilden, Germany) vRNA extraction kit. The NS3
region was targeted for amplification by nested RT-PCR by
using Titan one tube RT-PCR kit (Roche) and the Expand
High Fidelity PCR system (Roche). Specific primers were
designed for Genotype 1a and 1b based on alignments of
available sequences from the public HCV Database (http://
hcv.lanl.gov) [23]. PCR products were obtained with the
following primers: primer 1- TTACGTATTCCACCTAT
GGC, primer 2 - GACACATCAAGACCCCGGTA, for the
round of the RT-PCR following by primers: 3-GAC
ACATCAAGACCCCGGTA, and 4-ATGAGTGCCACT
CAACTGAC, purified and cloned in pCR-TOPO
(Invitrogen). After cloning, amplified fragments were
sequenced in both directions by using the BigDye
Terminator version 1.1 cycle sequencing kit (Applied
Biosystems) and ABI Prism 3100 genetic analyzer (PE/
Applied Biosystem). Sequence analysis was carried out
with Vector NTI suite (Invitrogen). The sequences were
analyzed by using nucleotide blast (blastn) (http://blast.
ncbi.nlm.nih.gov/Blast.cgi) and ClustalX (v1.4) for align-
ment with previously described sequences.
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